Affiliations: [a] Molecular Memory Research Unit, The Wallenberg Laboratory, Skåne University Hospital (SUS) Malmö, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden | [b] Clinical Memory Research Unit, The Neuropsychiatric Clinic, Skåne University Hospital (SUS) Malmö, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden
Correspondence:
[*]
Correspondence to: Henrietta M Nielsen, PhD, Lund University, Dept of Clinical Sciences Malmö, Molecular Memory Research Unit, The Wallenberg Laboratory 2nd floor, Skåne University Hospital Malmö entrance 46, 205 02 Malmö, Sweden. Tel.: +46 40 335733; Fax: +46 40 337041; E-mail: [email protected].
Abstract: Neurodegenerative dementia, most frequently represented by Alzheimer's disease (AD) and dementia with Lewy bodies (DLB), is often accompanied by altered sleeping patterns and excessive daytime sleepiness. Studies showing an association between the neuropeptide orexin and AD/DLB-related processes such as amyloid-β (Aβ)1-42 plaque formation, α-synuclein accumulation and inflammation indicate that orexin might play a pathogenic role similar to the situation in narcolepsy. Our study of patients with AD (n = 26), DLB (n = 18), and non-demented controls (n = 24) shows a decrease in cerebrospinal fluid (CSF) orexin concentrations in DLB versus AD patients and controls. The observed differences in orexin levels were found to be specific to female DLB patients. We also show that the female DLB patients exclusively displayed lower levels of α-synuclein compared to AD patients and controls. Orexin was linked to α-synuclein and total-tau in female non-demented controls whereas associations between orexin and Aβ1-42 concentrations were absent in all groups regardless of gender. Thus, the proposed links between orexin, Aβ, and α-synuclein pathology could not be monitored in CSF protein concentrations. Interestingly, α-synuclein was strongly correlated to the CSF levels of total-Tau in all groups, suggesting α-synuclein to be an unspecific marker of neurodegeneration. We conclude that lower levels of CSF orexin are specific to DLB versus AD and appear unrelated to Aβ1-42 and α-synuclein levels in AD and DLB. Alterations in CSF orexin and α-synuclein levels may be related to gender which warrants further investigation.
Keywords: Alpha-synuclein, Alzheimer's disease, biomarker, dementia with Lewy bodies, orexin
